石藥集團(01093.HK)"鹽酸普拉克索片"獲藥品註冊批件
格隆匯1月2日丨石藥集團(01093.HK)公告,公司附屬公司石藥集團歐意藥業有限公司開發的"鹽酸普拉克索片(0.25mg、1.0mg)"已獲中華人民共和國國家藥品監督管理局頒發藥品註冊批件,為國內該品種首家視同通過仿製藥質量和療效一致性評價及第二家獲批仿製藥。
鹽酸普拉克索為神經系統疾病藥物,適用於治療1)成人特發性帕金森病,在整個疾病過程中(包括疾病後期),當左旋多巴的療效逐漸減弱或者出現變化和波動時,都可單獨使用(無左旋多巴)或與左旋多巴聯用;及2)中度至重度特發性不寧腿綜合症。
該產品的獲批將進一步豐富本集團的產品綫,有助於本集團在神經系統疾病領域的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.